• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0
  • HEK293 expressed
  • Endotoxin-free
  • Animal-component free

HumanKine® recombinant human IL-3 protein

Activity

0.4-2.0 ng/mL

Specific Activity

minimally 5.0 x 105 IU/mg

Species Reactivity

human

Purity

>95%

Cat No : HZ-1074

Print datasheet

Synonyms

Hematopoietic growth factor, IL 3, IL3, IL-3, Interleukin 3, Mast cell growth factor, MCGF, MULTI CSF, P cell stimulating factor

Validation Data Gallery

  • Purity of recombinant human IL-3 was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue.

    Purity of recombinant human IL-3 was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue.

  • Recombinant human IL-3 (HZ-1074) stimulates dose-dependent proliferation of the TF-1 human erythroleukemic indicator cell line. Cell number was quantitatively assessed by PrestoBlue® Cell Viability Reagent. TF-1 cells were treated with increasing concentrations of recombinant IL-3 for 72 hours. The EC50 was determined using a 4-parameter non-linear regression model. The EC50 range is 0.4-2.0 ng/mL

    Recombinant human IL-3 (HZ-1074) stimulates dose-dependent proliferation of the TF-1 human erythroleukemic indicator cell line. Cell number was quantitatively assessed by PrestoBlue® Cell Viability Reagent. TF-1 cells were treated with increasing concentrations of recombinant IL-3 for 72 hours. The EC50 was determined using a 4-parameter non-linear regression model. The EC50 range is 0.4-2.0 ng/mL

Technical Specifications

GeneID 3562
Species Human
Expression HEK293
Activity 0.4-2.0 ng/mL
Specific Activityminimally 5.0 x 105 IU/mg
Purity >95%
Endotoxin<1 EU/µg
Accession NumberP08700
Molecular Mass 17 to 50 kDa reduced and non-reduced, monomer, glycosylated
Formulation 1xPBS, See Certificate of Analysis for details
Species Reactivity human

Stability and Reconstitution

Stability and StorageProduct FormTemperature ConditionsStorage Time
(From Date of Receipt)
Lyophilized-20°C to -80°CUntil Expiry Date
LyophilizedRoom Temperature2 weeks
Reconstituted as per CofA-20°C to -80°C6 months
Reconstituted as per CofA4°C1 week
Avoid repeated freeze-thaw cycles.
Reconstitution Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein to 0.2 mg/mL in sterile 1xPBS pH 7.4. Gently swirl or tap vial to mix.

Background

Interleukin-3 (IL-3) is a multilineage hematopoietic growth factor that promotes the proliferation, differentiation and survival of early multilineage hematopoietic progenitors. In particular, this cytokine plays a key role in stimulating the proliferation and survival of myeloid precursors. It is involved in a variety of cell activities such as cell growth, differentiation and apoptosis. This cytokine has been shown to also possess neurotrophic activity, and it may be associated with neurologic disorders (PMID: 24103757;2698876;2809196)

Synonyms

Hematopoietic growth factor, IL 3, IL3, IL-3, Interleukin 3, Mast cell growth factor, MCGF, MULTI CSF, P cell stimulating factor

Publications

SpeciesTitle
human

Blood

LIN28B-mediated expression of fetal hemoglobin and production of fetal-like erythrocytes from adult human erythroblasts ex vivo.

Authors - Y TerryLee
View Article
human

J Exp Med

Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML.

Authors - AndrewVolk
View Article
human

Mol Cancer Ther

IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.

Authors - YelenaKovtun
View Article
human

Oncotarget

Sensitizing leukemia stem cells to NF-κB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signaling.

Authors - JingLi
View Article
human

Eur J Pharmacol

Ginsenoside Rg1 promotes fetal hemoglobin production in vitro: A potential therapeutic avenue for β-thalassemia

Authors - Dong-Ling Cai
View Article
human

Biochem Pharmacol

The new mitochondrial uncoupler BAM15 induces ROS production for treatment of acute myeloid leukemia.

Authors - Zhen Xing Gao
View Article